Article Text

other Versions

Download PDFPDF
Adding aspirin to antipsychotics reduces psychopathology in adults with schizophrenia spectrum disorders

Statistics from



Does adjuvant aspirin benefit patients with schizophrenia spectrum disorders who are on antipsychotic therapy?


70 adults (18–55 years of age) with DSM-IV schizophrenia spectrum disorder (schizophrenia, schizoactive disorder or schizophreniform disorder), who were at least moderately ill (score ≥60 on the Positive and Negative Syndrome Scale, PANSS, with score ≥4 on two items). There was a 2-week placebo run-in period, and only those who achieved over 80% compliance were randomised. Exclusion criteria: illness duration longer than 10 years (changed from 5 years because of slow recruitment), contraindications for aspirin or pantoprazole, significant somatic illness, chronic non-steroidal anti-inflammatory drug use, corticosteroid use, pregnancy or change in type or dose of antipsychotic drugs in the previous 2 weeks.


10 psychiatric hospitals in The Netherlands; May 2004 to August 2007.


Adjuvant aspirin (1000 mg daily) or placebo (adjuvant to antipsychotic …

View Full Text


  • Source of funding The Stanley Medical Research Institute.


  • Competing interests None.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.